Mar 22, 2002|
Cadila: Margins under pressure
The third quarter results of Cadila Healthcare show a sharp improvement in topline growth. As against a 7% growth in the first half of the current year, the company has logged a growth rate of almost 30% in the third quarter. However, the drop in operating margins is somewhat disappointing. The company however, seems to be on the fast track on its way up through the inorganic route.
|Operating Profit (EBDIT)
|Operating Profit Margin (%)
|Interest Exp/ (Income)
|Profit before Tax
|Profit after Tax/(Loss)
|Net profit margin (%)
|No. of Shares (eoy) (m)
|Diluted Earnings per share*
|P/E (at current price)
The strong growth rate has been possible due to launch of new products in the neuroscience division, acquisition of perpetual rights to market five leading brands from Asta and acquisition of 'Aten' brand from Kopran last year. Further the company has also logged several co-marketing alliances with Kopran, Ranbaxy and E-Merck. However, margins in this business are low compared to other businesses which partially explains the drop in overall margins.
The company has ambitious plans to emerge amongst the top 3 pharmaceutical companies in India by March 2004. To achieve the same, the company has invested heavily in creating large scale capacities which would help it sustain growth momentum in coming times. Realising its over dependence on few slow growing therapeutic segments, the company has made some rapid moves, including acquisitions, which will strongly position the company in some of the fast growing therapeutic segments.
Though domestic growth is likely to be low in current year, the growth would pick up from next year, once the additional manufacturing capacity goes on stream. Further, the merged numbers with German Remedies would show a robust picture of the company. The research initiatives of the company are also capable of giving surprises going forward.
However, what is concerning is the rising interest burden on the company. The debt amount of the company has rose considerably in last one year to fund its acqusitions and research initiatives. The payback period of these acquisitions would have to justify the rise in interest costs. The valuations of the company going forward would thus depend on how fast the debt backed acquisitions of the company payoff. At the current market price of Rs 125, the stock trades at 12x its third quarter annualised earnings.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
Aug 16, 2017
The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407